SQZ’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

SQZ is a biotechnology company that develops and commercializes cell therapies for the treatment of cancer and autoimmune diseases. Read more

31 Followers on Owler
31 Followers on Owler
31 Followers on Owler
31 Followers on Owler

SQZ is a biotechnology company that develops and commercializes cell therapies for the treatment of cancer and autoimmune diseases. Read more

Armon Sharei's photo - Founder & CEO of SQZ

Founder & CEO

Armon Sharei

CEO Approval Rating

88/100

Founded:

2013

Status:

PublicIndependent CompanyNYSESQZ

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

CytomX is SQZ's #1 competitor. CytomX's headquarters is in South San Francisco, California, and was founded in 2008. Like SQZ, CytomX also works within the Biotechnology sector. CytomX generates 458% of SQZ's revenue.

Cleveland BioLabs is one of SQZ's top rivals. Cleveland BioLabs was founded in Buffalo, New York} in 2003. Cleveland BioLabs operates in the Pharmaceuticals industry. Compared to SQZ, Cleveland BioLabs generates $19.5M less revenue.

Onconova is one of SQZ's top competitors. Onconova is a Public company that was founded in 1998 in Newtown, Pennsylvania. Onconova is in the Pharmaceuticals industry. Compared to SQZ, Onconova has 84 fewer employees.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Oncolinx a competitor of SQZ?

Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$20.1M

SQZ's revenue is the ranked 4th among it's top 10 competitors. The top 10 competitors average 17.2M. Over the last one quarters, SQZ's revenue has decreased by 0%. Specifically, in Q4 2019's revenue was $20.1M.

Acquisitions

No recent acquisitions found related to SQZ

SQZ Funding History

$1M$6.1M$30.1M$102.1M$167.1M$258.5M

Since SQZ was founded in 2013, it has participated in 7 rounds of funding. In total SQZ has raised $258.5M. SQZ's last funding round was on Oct 2020 for a total of $91.3M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

IPO
Oct 2020
$91.3M

Series D
Dec 2019
$65M
Series C
May 2018
$72M
Equity
Dec 2017
--
Series B
Sep 2016
$24.1M

Since SQZ was founded in 2013, it has participated in 7 rounds of funding. In total SQZ has raised $258.5M. SQZ's last funding round was on Oct 2020 for a total of $91.3M

Investments

No recent investments found related to SQZ

SQZ News

November 3, 2020Global University Venturing

SQZ Bio squeezes on to NYSE - Global University Venturing

The MIT cell therapy spinout priced its shares at the bottom of their range to raise $70.6m, followin... See more »
October 30, 2020The Business Journals

Watertown biotech SQZ starts trading after $71M IPO

A decade ago, Armon Sharei stumbled across a simple method of getting things inside cells to create t... See more »
October 30, 2020Seeking Alpha

SQZ Biotech prices IPO at $16

October 27, 2020Boston Citybizlist

SQZ Biotechnologies Seeks $75 Million IPO

May 21, 2020Forbes

Meet The MIT PhD Who Just Raised $65 Million For His Clinical Stage Cell Therapy Company

Armon Sharei's SQZ Biotech announced it raised a $65 Million-Series D round, led by Temasek with part... See more »

SQZ Press Releases

January 30, 2020GlobalNewswire

SQZ Biotech Announces First Patient Dosed in Phase 1 Trial of SQZ-PBMC-HPV for HPV+ Tumors

Trial is evaluating SQZ-PBMC-HPV as both monotherapy and in combination with a checkpoint inhibitor... See more »
October 22, 2019GlobalNewswire

SQZ Biotech Announces Clearance of US IND Application for First Clinical Trial

First program advancing into the clinic through the SQZ-Roche collaboration in APCs for oncologyFirst... See more »
September 17, 2019GlobalNewswire

SQZ Biotech Appoints Legal Life Sciences Expert, Lawrence Knopf, as General Counsel

WATERTOWN, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- SQZ Biotechnologies (SQZ), a cell therapy compan... See more »
May 29, 2019GlobeNewswire

SQZ Biotech Strengthens Board of Directors with Appointment of Leading Cell Therapy Expert and Biotech Veteran

Isaac Ciechanover, MD, MBA, to join board of directors as SQZ prepares to enter the clinic with its i... See more »
May 14, 2019GlobeNewswire

SQZ Biotech to Present at Investor Conferences in May & June

WATERTOWN, Mass., May 14, 2019 (GLOBE NEWSWIRE) -- SQZ Biotechnologies (SQZ), a cell therapy company ... See more »
April 25, 2019GlobeNewswire

SQZ Biotech to Present at the American Society of Gene and Cell Therapy (ASGCT) 22nd Annual Meeting

WATERTOWN, Mass., April 25, 2019 (GLOBE NEWSWIRE) -- SQZ Biotechnologies (SQZ), a cell therapy compan... See more »
March 28, 2019GlobeNewswire

SQZ Biotech to Present at the Jefferies Immuno-Oncology Cell Therapy Summit

WATERTOWN, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- SQZ Biotechnologies (SQZ), a cell therapy compan... See more »

Social Media

Headquarters

200 Arsenal Yards Boulevard

Watertown, Massachusetts02472

617-758-8672

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

SQZ is a biotechnology company that develops and commercializes cell therapies for the treatment of cancer and autoimmune diseases. SQZ was founded in 2013. SQZ's headquarters is located in Watertown, Massachusetts, USA 02472. It has raised 258.5M in ...

CEO

SQZ's Founder & CEO, Armon Sharei, currently has an approval rating of 88%. SQZ's primary competitors are CytomX, Cleveland BioLabs & Onconova.

Website

sqzbiotech.com

Frequently Asked Questions about SQZ

  1. When was SQZ founded?

    SQZ was founded in 2013
  2. Who is SQZ's CEO?

    SQZ's CEO is Armon Sharei
  3. How much revenue does SQZ generate?

    SQZ generates $20.1M in revenue
  4. How much funding does SQZ have?

    SQZ has historically raised $258.5M in funding
  1. Where is SQZ's headquarters?

    SQZ's headquarters is in Watertown Massachusetts, USA
  2. How many employees does SQZ have?

    SQZ has 101 employees
  3. What sector does SQZ operate in?

    SQZ is in Biotechnology, Pharmaceuticals
  4. Who are SQZ's competitors?

    SQZ's top competitors are CytomX, Cleveland BioLabs, Onconova